Kieran O'Kane - May 9, 2022 Form 4 Insider Report for BIODESIX INC (BDSX)

Signature
/s/ Robin Harper Cowie as Attorney-in-Fact for Kieran O'Kane
Stock symbol
BDSX
Transactions as of
May 9, 2022
Transactions value $
-$2,897
Form type
4
Date filed
5/11/2022, 09:42 PM
Previous filing
Feb 10, 2022
Next filing
Aug 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BDSX Common Stock Options Exercise +5.46K +145.2% 9.22K May 9, 2022 Direct F1, F6
transaction BDSX Common Stock Sale -$2.9K -1.58K -17.17% $1.83 7.64K May 10, 2022 Direct F4, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BDSX Restricted Stock Units Options Exercise $0 -1.49K -6.25% $0.00 22.3K May 9, 2022 Common Stock 1.49K Direct F1, F2
transaction BDSX Restricted Stock Units Options Exercise $0 -3.97K -16.67% $0.00 19.9K May 9, 2022 Common Stock 3.97K Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Issuer common stock (each, a "Share").
F2 These RSUs vest in a series of sixteen successive quarterly installments measured from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.
F3 These RSUs vest in a series of six successive quarterly installments from February 8, 2022, generally subject to the reporting person's continued service with the Issuer, and have no expiration date.
F4 These Shares were sold automatically to cover taxes upon the vesting of RSUs.
F5 The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $1.73 to $1.945, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 Includes 1,157 and 2,604 Shares acquired under the BDSX stock purchase plan on August 31, 2021 and February 28, 2022, respectively.